MarketScreener Homepage > Equities > NASDAQ COPENHAGEN A/S > Novo Nordisk A/S NOVO B DK0060534915

Report

Delayed NASDAQ COPENHAGEN A/S - 03/05 10:59:58 am
427.1	DKK		-1.76%

03/05

DANCANN PHARMA A/S : appoints Malene Gottfredsen as Product Manager

03/05

NOVO NORDISK : Deutsche Bank maintains a Buy rating

03/04

NOVO NORDISK : Goldman Sachs remains its Buy rating

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq Copenhagen A/s

03/01/2021	03/02/2021	03/03/2021	03/04/2021	03/05/2021	Date
448.55(c)	448.3(c)	438.9(c)	434.75(c)	427.1(c)	Last
2 139 514	1 794 484	1 947 786	2 720 503	2 679 650	Volume
+2.42%	-0.06%	-2.10%	-0.95%	-1.76%	Change

More quotes

Financials

Sales 2021	133 B 21 284 M 21 284 M
Net income 2021	44 241 M 7 090 M 7 090 M
Net cash position 2021	8 830 M 1 415 M 1 415 M
P/E ratio 2021	22,2x
Yield 2021	2,28%

Sales 2022	144 B 23 083 M 23 083 M
Net income 2022	48 303 M 7 741 M 7 741 M
Net cash position 2022	13 046 M 2 091 M 2 091 M
P/E ratio 2022	19,8x
Yield 2022	2,47%

Capitalization	986 B 158 B 158 B
EV / Sales 2021	7,36x
EV / Sales 2022	6,76x
Nbr of Employees	45 023
Free-Float	75,1%

More Financials

Company

Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of...

Sector

Pharmaceuticals

Calendar

03/25 | 08:00am

Shareholder meeting

More about the company

Notations Surperformance© of Novo Nordisk A/S

Trading Rating :

Investor Rating :

More Ratings

All news about NOVO NORDISK A/S

03/05	DANCANN PHARMA A/S : appoints Malene Gottfredsen as Product Manager	AQ
03/05	NOVO NORDISK : Deutsche Bank maintains a Buy rating	MD
03/04	NOVO NORDISK : Goldman Sachs remains its Buy rating	MD
03/02	NOVO NORDISK A/S : Press Release	CO
03/01	PRESS RELEASE : Evotec and Chinook Therapeutics enter into strategic collaborati..	DJ
02/26	NOVO NORDISK A/S : invests DKK 500 million in expanding tablet production facil..	AQ
02/26	NOVO NORDISK A/S : To Invest $81.5 Million To Expand Danish Production Site	MT
02/25	NOVO NORDISK A/S : and the University of Toronto announce joint 200 DKK million..	AQ
02/23	NOVO NORDISK A/S : Notice for the Annual General Meeting of Novo Nordisk A/S	AQ
02/22	NOVO NORDISK A/S : Aeterna Zentaris Announces Closing of $29.7 Million Bought D..	AQ
02/22	NOVO NORDISK A/S : – Share repurchase programme	AQ
02/18	NOVO NORDISK : UBS reaffirms its Neutral rating	MD
02/18	NOVOTEK AB : Bokslutskommuniké januari - december -2-	DJ
02/16	NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives ..	AQ
02/16	NOVO NORDISK : Deutsche Bank remains its Buy rating	MD

More news

News in other languages on NOVO NORDISK A/S

03/04	Aktien Europa Schluss: Überwiegend Verluste - Vorsicht wegen Zinssorgen
03/04	DGAP-HV : Covestro AG: Bekanntmachung der -6-
02/10	Calme en surface, bouillonnant en dessous
02/08	Börse Stuttgart-News: Euwax Trends
02/03	Aktien Europa Schluss: Uneinheitlich - Erleichterungsgewinne in Mailand

More news

Analyst Recommendations on NOVO NORDISK A/S

03/05	NOVO NORDISK : Deutsche Bank maintains a Buy rating	MD
03/04	NOVO NORDISK : Goldman Sachs remains its Buy rating	MD
02/18	NOVO NORDISK : UBS reaffirms its Neutral rating	MD

More recommendations

Stock Trading Strategies

	NOVO NORDISK A/S - 2020
A good level to buy

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Global equities rise on strong earnings, oil gains

More Must read

Chart NOVO NORDISK A/S

Duration : Period :

Novo Nordisk A/S Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends NOVO NORDISK A/S

	Short Term	Mid-Term	Long Term
Trends	Neutral	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	HOLD
Number of Analysts	28
Average target price	466,85 DKK
Last Close Price	427,10 DKK
Spread / Highest target	28,8%
Spread / Average Target	9,31%
Spread / Lowest Target	-22,7%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Lars Fruergaard Jørgensen	President & Chief Executive Officer
Karsten Munk Knudsen	Chief Financial Officer & Executive Vice President
Helge Lund	Chairman
Mads Krogsgaard Thomsen	Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff	Executive VP & Head-Information Technology

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

NOVO NORDISK A/S	1.90%	157 942



JOHNSON & JOHNSON	-0.81%	410 337
ROCHE HOLDING AG	-1.63%	274 753
PFIZER INC.	-7.09%	191 873
ABBVIE INC.	-0.42%	188 420
ELI LILLY AND COMPANY	22.55%	187 971

More Results